TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Show more
830 Winter Street, Waltham, MA, 02451, United States
Market Cap
59.75M
52 Wk Range
$0.88 - $2.57
Previous Close
$1.13
Open
$1.15
Volume
650,947
Day Range
$1.04 - $1.16
Enterprise Value
1.479M
Cash
152.4M
Avg Qtr Burn
-32.0M
Insider Ownership
0.23%
Institutional Own.
65.76%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TSC-101 Details Acute Myeloid Leukemia (AML), Acute lymphoblastic leukemia (ALL), Myelodysplastic syndrome (MDS) | Phase 1 Data readout | |
TSC-102-A01/TSC-102-A03 (TCR-T Therapy) Details Hematologic Malignancies Following Allogeneic HCT | Phase 1 Initiation | |
Failed Discontinued |